Nosopharm, a company dedicated to the research and development of new anti-infective drugs, has named Jacques Biton as its new chairman of the board, taking over from Gilles Alberici.
At the CPhI Worldwide in Frankfurt, the winners of the 2019 Pharma awards were announced. The CEO of WuXi AppTec, Dr. Ge Li, received the award in category CEO of the year among 12 other categories.
A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE programme of the Innovative Medicines Initiative (IMI).
Swiss specialty pharmaceutical company Santhera has named Dario Eklund as new CEO. Eklund joins from Vifor Pharma, where he served as Chief Commercial Officer.
Bergen Bio ASAs Axl kinase blocker bemcentinib in combination with MSDs pembrolizumab has met the primary endpoint in a Phase II study in patients with non small cell lung cancer (NSCLC).
German researchers have designed a modified Sleeping Beauty transposase that can be used for non-viral, stable and efficient gene insertions for gene and CAR-T therapies.
Despite challenging markets new players are entering the field to advance drug development in the fight against antimicrobial resistance.
Renowned immunologist Iain McInnes has been appointed to the Scientific Advisory Boar of Oxford BioDynamics Plc, where he joins Karol Sikora, Jane Mellor and Lucien Peng-Jin Ooi.
BioEcho develops single-spin and 96-well kits for the isolation of DNA from different starting materials. In contrast to common bind-wash-elute procedures their proprietary EchoLUTION single-step technology avoids the use of inhibitory or harmful process reagents and does not require washing steps.